RT Journal Article
T1 COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.
A1 Busca, Alessandro
A1 Salmanton-García, Jon
A1 Corradini, Paolo
A1 Marchesi, Francesco
A1 Cabirta, Alba
A1 Di Blasi, Roberta
A1 Dulery, Remy
A1 Lamure, Sylvain
A1 Farina, Francesca
A1 Weinbergerová, Barbora
A1 Batinić, Josip
A1 Nordlander, Anna
A1 López-García, Alberto
A1 Drgoňa, Ľuboš
A1 Espigado-Tocino, Ildefonso
A1 Falces-Romero, Iker
A1 García-Sanz, Ramón
A1 García-Vidal, Carolina
A1 Guidetti, Anna
A1 Khanna, Nina
A1 Kulasekararaj, Austin
A1 Maertens, Johan
A1 Hoenigl, Martin
A1 Klimko, Nikolai
A1 Koehler, Philipp
A1 Pagliuca, Antonio
A1 Passamonti, Francesco
A1 Cornely, Oliver A
A1 Pagano, Livio
AB The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/20249
UL http://hdl.handle.net/10668/20249
LA en
DS RISalud
RD Apr 7, 2025